TY  - RPRT
TI  - A novel neoadjuvant immunotherapy confers improved overall survival in oral cancer patients with low tumor PD-L1 expression The IT-MATTERS Clinical trial - Prognostic role of tumor PD-L1 expression.
AU  - Eyal Talor
AU  - Philip Lavin
AU  - John Cipriano
AU  - Dusan Markovic
AU  - Andrea Ladányi
AU  - József Tímár
AU  - IT-MATTERS Investigators
PY  - 2026
DO  - 10.1016/j.oraloncology.2026.108092
UR  - https://pubmed.ncbi.nlm.nih.gov/42537452/
ID  - 42537452
ER  -